MDM2 and glioblastoma: In orthotopic glioblastoma (GBM) patient-derived brain tumor stem cell (BTSC) xenograft models, treatment with the MDM2 small molecule inhibitor brigimadlin (BI-907828) showed higher survival rates compared to the control group [188].